Serotonin and dopamine receptors in motivational and cognitive disturbances of schizophrenia by Tomiki Sumiyoshi et al.
HYPOTHESIS AND THEORY ARTICLE
published: 04 December 2014
doi: 10.3389/fnins.2014.00395
Serotonin and dopamine receptors in motivational and
cognitive disturbances of schizophrenia
Tomiki Sumiyoshi1*, Hiroshi Kunugi2 and Kazuyuki Nakagome3
1 Department of Clinical Research Promotion, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan
2 Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan
3 National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan
Edited by:
Bettina Bert, Freie Universiät Berlin,
Germany
Reviewed by:
Doris Doudet, Aarhus University,
Aarhus University Hospital,
Denmark
Yukihiro Ohno, Osaka University of
Pharmaceutical Sciences, Japan
*Correspondence:
Tomiki Sumiyoshi, Department of
Clinical Research Promotion,
National Center Hospital, National




Negative symptoms (e.g., decreased spontaneity, social withdrawal, blunt affect) and
disturbances of cognitive function (e.g., several types of memory, attention, processing
speed, executive function, fluency) provide a major determinant of long-term outcome
in patients with schizophrenia. Specifically, motivation deficits, a type of negative
symptoms, have been attracting interest as (1) a moderator of cognitive performance
in schizophrenia and related disorders, and (2) a modulating factor of cognitive
enhancers/remediation. These considerations suggest the need to clarify neurobiological
substrates regulating motivation. Genetic studies indicate a role for the monoamine
systems in motivation and key cognitive domains. For example, polymorphism of genes
encoding catecholamine-O-methyltransferase, an enzyme catabolizing dopamine (DA),
affects performance on tests of working memory and executive function in a phenotype
(schizophrenia vs. healthy controls)-dependent fashion. On the other hand, motivation to
maximize rewards has been shown to be influenced by other genes encoding DA-related
substrates, such as DARPP-32 and DA-D2 receptors. Serotonin (5-HT) receptors may also
play a significant role in cognitive and motivational disabilities in psychoses and mood
disorders. For example, mutant mice over-expressing D2 receptors in the striatum, an
animal model of schizophrenia, exhibit both decreased willingness to work for reward
and up-regulation of 5-HT2C receptors. Taken together, genetic predisposition related to
5-HT receptors may mediate the diversity of incentive motivation that is impaired in
patients receiving biological and/or psychosocial treatments. Thus, research into genetic
and neurobiological measures of motivation, in association with 5-HT receptors, is likely to
facilitate intervention into patients seeking better social consequences.
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INTRODUCTION
Disturbances of mental processes, including cognitive function
(e.g., several types of memory, attention, processing speed, and
executive function, fluency) and motivation characterize many
of the psychiatric illnesses, such as schizophrenia, mood disor-
ders, and substance abuse (Simpson et al., 2011; Choi et al.,
2014; Sumiyoshi, in press). Recently, the development of bio-
logical (e.g., pharmacotherapy and brain stimulation) and psy-
chosocial (e.g., cognitive rehabilitation) interventions is targeting
social function/adaptation as an important outcome measure
(Harvey et al., 2011; Leifker et al., 2011). In this context, negative
symptoms (decreased spontaneity, social withdrawal, and blunt
affect) and cognitive impairment provide a major determinant
of long-term outcome. Specifically, motivation deficits have been
attracting interest as a moderator of (1) cognitive performance in
patients with schizophrenia and related disorders, and (2) benefi-
cial influence of cognitive enhancers/remediation (Fervaha et al.,
2014; Strauss et al., 2014). These considerations suggest the need
to clarify neurobiological substrates regulating motivation for
improving quality of life in a rational and effective manner.
We herein present a theory/hypothesis that the research into
genetic and neurobiological measures of motivation, linked to
serotonin (5-HT) receptors, would facilitate treatment of patients
with schizophrenia or other psychiatric illnesses.
MOTIVATIONAL DISTURBANCES IN SCHIZOPHRENIA
Schizophrenia is characterized by a range of symptoms, e.g., pos-
itive symptoms (delusions, hallucinations, thought disorders),
negative symptoms, mood symptoms, and cognitive impairment.
Specifically, there is a suggestion that negative symptoms can
be separated into two domains; (1) a motivational dimension,
consisting of avolition, anhedonia, and asociality, and (2) a
diminished expressivity dimension, consisting of restricted affect
and alogia (Strauss et al., 2014). There is a general consensus
that motivational disturbances may overlap some (e.g., anhedo-
nia), but not all (e.g., blunt affect, alogia) aspects of negative
symptoms. The former dimension has been considered to be of
greater importance in terms of functional outcome, quality of
life, and recovery from the disease (Strauss et al., 2014). Whether
other aspects of symptomatology of schizophrenia (e.g., mood
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symptoms) may substantially affect motivation in patients or
vulnerable people remains to be determined (Schlosser et al.,
2014).
DOPAMINE (DA) SYSTEMS GOVERNING MOTIVATION AND
COGNITION
The neural basis for intrinsic motivation has been an issue of
extensive research. For example, activity of the anterior stria-
tum and prefrontal cortex (PFC), measured by the functional
MRI, has been shown to be associated with intrinsic motivation
(Murayama et al., 2010). This line of anatomical evidence is con-
sistent with genetic studies indicating a role for the monoamine
systems in cognition and motivation, as discussed below.
The Val158Met polymorphism of the genes encoding
catecholamine-O-methyltransferase (COMT), an enzyme catab-
olizing DA, affects performance on tests of working memory
and executive function in a phenotype (schizophrenia vs. healthy
controls)-dependent fashion (Egan et al., 2001). Thus, individ-
uals with the val/val carriers in COMT show greater efficacy
of the enzyme, leading to decreased DA levels in the PFC. The
enzyme has also been suggested to mediate uncertainty-based
exploration that is linked to DA levels in the PFC. For example,
individuals with at least one met-allele show enhanced explo-
ration compared to those with val/val genotype (Frank et al.,
2007).
On the other hand, motivation to maximize rewards has been
shown to be influenced by other DA-related genes expressed in the
striatum/nucleus accumbens (NAc). Specifically, reward learn-
ing and negative reward avoidance are affected by genotypes of
a polymorphism (rs907094. A/G) of the gene encoding DARPP-
32 (a protein required for synaptic plasticity and reward learning
mediated by DA-D1 receptors) and the D2 receptor (related to
avoidance of negative outcomes), respectively (Frank et al., 2007;
Klein et al., 2007). Thus, individuals with T/T genotype show
greater expression of mRNA for the DARPP-32 gene, leading to
greater performance to maximize rewards compared to C-allele
carriers (reviewed in Frank et al., 2009). Similarly, T/T carriers
of genes encoding D2 receptors are associated with greater den-
sity of these receptors in the striatum and greater likelihood to
maximize rewards (Hirvonen et al., 2004; Frank et al., 2007). A
recent study (Simpson et al., 2013) reported that overexpression
of D3 receptors, a member of the D2 receptor family, in the stria-
tum selectively impaired incentive motivation, as measured by an
operant task.
The mechanisms by which DA receptors govern motiva-
tion and cognitive functions may involve timing perception.
For example, genetically-engineered mice overexpressing D2
receptors in the striatum have been shown to elicit impaired
working memory, behavioral flexibility and sensorimotor gat-
ing, i.e., behavioral abnormalities reminiscent of schizophrenia
(Kellendonk et al., 2006). These model animals also demon-
strate reduced motivation, as well as alteration of interval timing
organization, as measured by the operant timing task (Drew
et al., 2007). Further studies indicate that the impaired timing
in these mutant mice mediates the ability of decreased motiva-
tion to worsen cognitive functions, including working memory
and attention (Ward et al., 2009). These lines of evidence suggest
a strategy for the intervention into motivational disturbances, in
terms of biological and/or tailor-made treatments.
Figure 1 summarizes a concept about how genes encoding
these DA-related substrates contribute to cognitive and
motivational behaviors.
FIGURE 1 | Genes in the dopaminergic motivational system.
Polymorphisms of genes encoding DARPP-32 and dopamine (DA)-D2
receptors (DRD2) affect behaviors to maximize rewards, while the
polymorphism in COMT are associated with uncertainty-based
exploration. Information in the Figure was extracted from Frank et al.
(2009).
Frontiers in Neuroscience | Neuropharmacology December 2014 | Volume 8 | Article 395 | 2
Sumiyoshi et al. Serotonin receptors and motivation
5-HT RECEPTOR SUBTYPES IN MOTIVATION-RELATED
BEHAVIORS
5-HT receptors, e.g., 5-HT1A, 5-HT2A, and 5-HT2C subtypes, may
also play a role in cognitive and motivational disabilities in psy-
choses andmood disorders (Meltzer andMassey, 2011; Newman-
Tancredi and Albert, 2012; Ohno et al., 2012). For example, sev-
eral antipsychotic and antidepressant drugs have been suggested
to ameliorate negative symptoms and mood disturbances, partly
through actions on 5-HT1A and 5-HT2A receptors (Newman-
Tancredi and Albert, 2012; Ohno et al., 2012; Sumiyoshi et al.,
2013; Sumiyoshi, 2014). Clozapine, the prototype of atypical
antipsychotic drugs, which is most effective in treating negative
symptoms, may act as an inverse agonist on 5-HT2C receptors
(Meltzer and Massey, 2011).
Data from recent investigations support the contribution of
5-HT receptors to motivational behaviors. For example, mutant
mice over-expressing D2 receptors in the striatum, exhibit both
decreased willingness to work for reward and up-regulation of
5-HT2C receptors (Simpson et al., 2011). Furthermore, increased
D1, D2 and 5-HT2C receptors co-exist in mice mis-expressing
ADAR2, an RNA-editing enzyme, and these animals elicit altered
expression of reward-related mRNAs in the brain (Akubuiro
et al., 2013). Collectively, these observations indicate the impor-
tance of some 5-HT receptor subtypes, e.g., 5-HT2C receptors, in
the pathophysiology and treatment of motivational disturbances
associated with psychoses (Figure 2).
The role for 5-HT2C receptors in psychiatric symptoms rel-
evant to functional outcome is also supported by observa-
tions in mice whose 5-HT-synthesizing enzyme (tryptophan
hydroxyxlase-2) was genetically engineered (Del’Guidice et al.,
2014). Thus, treatment with the 5-HT2C agonist CP809,101 ame-
liorated impairments in cognitive flexibility and reversal learning
in these mutant animals (Del’Guidice et al., 2014).
As noted above, up-regulation of 5-HT2c receptors in the stria-
tum may be associated with a decrease in incentive motivation
(Simpson et al., 2011). Further, 5-HT2c receptors localized in DA
and GABA neurons in the ventral tegmental area (VTA) also have
been suggested to regulate motivation by modulating transmis-
sions to NAc (Bubar et al., 2011) (Figure 2). It should be noted
that a proportion of NAc-projecting VTA neurons may release
both DA and GABA (Bubar et al., 2011). Altered balance in this
complicated 5-HT2c receptor-associated network is postulated to
cause reward-related disorders, such as schizophrenia, depression,
and addiction (Bubar et al., 2011).
Other 5-HT receptor subtypes, such as 5-HT1A and
5-HT2Areceptors, may directly or indirectly influence this
neural system for motivational behaviors as well. For exam-
ple, 5-HT1A receptor gene promotor polymorphism (rs6295,
C-1019G) has been associated with treatment effects on negative
symptoms of schizophrenia (Reynolds et al., 2006). Figure 2
illustrates a putative neural network mediating motivational
behaviors in relation to 5-HT receptors, which, together with
FIGURE 2 | A putative neural network mediating motivational
behaviors in relation to serotonin (5-HT) receptors. (1) Up-regulation of
5-HT2c receptors in the nucleus accumbens (NAc)/striatum may be
associated with a decrease in incentive motivation in mutant mice
over-expressing dopamine (DA)-D2 receptors in the striatum, an animal
model of schizophrenia (Simpson et al., 2011). SB242084, a selective
antagonist at these receptors, increases incentive motivation in these
model mice. (2) 5-HT2c receptors localized in DA and GABA neurons in the
ventral tegmental area (VTA) also affect motivation by modulating
transmissions to NAc, including actions on D1 and D2 receptors (Bubar
et al., 2011). The dotted line indicates that a proportion of NAc-projecting
VTA neurons releases both DA and GABA (Bubar et al., 2011). (3) Other
5-HT receptor subtypes, such as 5-HT1A and 5-HT2A, may also directly or
indirectly regulate this neural system of motivational behaviors.
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Figure 1 (upper part), may suggest the contribution of DA-5-HT
interactions.
CLINICAL PERSPECTIVES AND FUTURE DIRECTIONS
Based on the discussions so far, drugs acting on some 5-HT
receptor subtypes, particularly, 5-HT2C receptors, are likely to
improve motivational deficits in individuals with schizophrenia.
For example, SB242084, a selective antagonist at 5-HT2C recep-
tors, has been shown to increase incentive motivation in mice
over-expressing D2 receptors in the striatum, an animal model
of schizophrenia (Simpson et al., 2011). By contrast, the 5-HT2C
receptor agonist CP809,101 has been demonstrated to enhance
performance on some cognitive tasks in mice with decreased
5-HT synthesis (Del’Guidice et al., 2014). These preclinical obser-
vations warrant clinical studies of the effect of agents for specific
5-HT receptor subtypes, e.g., 5-HT2C receptors, on motivational
and cognitive disturbances. Specifically, it is important to see if
such putative pro-motivation drugs will lead to improvement of
functional outcome affected by cognitive function on which such
compounds might act in variable directions.
In view of a possible influence of motivation on cogni-
tive training, it may be interesting to determine if augmen-
tation with pro-motivation compounds, e.g., 5-HT2C agents,
would provide additional merits for cognitive and functional
outcome in patients with schizophrenia. Also, whether genetic
variations regarding 5-HT and/or DA receptors affect motiva-
tional response to treatment with existing pharmacological or
psychosocial interventions deserves further study.
In summary, genetic predisposition related to 5-HT and DA
receptors maymediate the diversity of incentive motivation that is
impaired in patients with schizophrenia. This concept is expected
to facilitate rational treatment with biological and/or psychosocial
tools to improve social consequences for people with psychiatric
illnesses.
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